Efficacy and Safety of the Novel Sirolimus-Eluting, Biodegradable Polymer Coated Stent in Human Coronary Lesions

Qiuping Shi,Ming Chen,Yukui Zhang,Bin Zhang,Bo Zheng,Xingang Wang,Yong Huo

2014-01-01

Abstract:The postulated relationship between nonbiodegradable polymers and LST has led to a concerted effort to seek alternative biodegradable polymers for drug delivery. Bioabsorbable coatings with a degradation period matched to that of the drug elution may be a better alternative, clinically and economically. The purpose of this study was to evaluate the safety and the efficacy of the novel sirolimus-eluting stent (SES) with biodegradable polylactic-co-glycolic acid (PLGA) polymeric matrix (Tivoli™, Essen Technology, Beijing, China) implantation in human atherosclerotic coronary. Seventeen patients with angina pectoris were enrolled in the study. The primary end points included the percentage of in-stent restenosis of the luminal diameter and in-stent late luminal loss at 8 months, as determined by quantitative angiography. The secondary end point was the major adverse cardiac events (MACE) 30 days and 9 months after stenting procedure. A total of 27 Tivoli™ SESs were implanted successfully in 23 lesions (22 de novo lesions and 1 ISR lesion), and all patients were discharged without clinical complications and completed 9-month clinical follow-up. Except for target vessel revascularization, no other major adverse cardiac events developed during clinical follow-up period. Thirteen patients (18 lesions, 22 stents) completed 8 months of angiographic follow-up. No in-sent or in-segment diameter restenosis was observed. The median of in-stent/ in-segment late loss is 0.1mm. Target vessel initial narrow (not target lesion restenosis) was occured in only one patient (5.9%), who underwent repeated PCI. Thus, both total MACE rate and the target vessel revascularization rate per patient were 5.9%.This study showed that Tivoli™ sirolimus-eluting cobalt-chromium stent coated with bioabsorbable PLGA polymer demonstrated a safe and efficacious clinical alternative to reduce restenosis.